申请人:TOPOTARGET AS
公开号:WO2009086835A1
公开(公告)日:2009-07-16
This application discloses novel cyanoguanidines of the formula (I) wherein A is selected from -C(=O)-, -S(=O)2-, -C(=S)-, and -P(=O)(R5)-, wherein R5 is selected from C1-6-alkyl, C1-6-alkoxy, and hydroxy; B is selected from a single bond, -O-, -NR6- and -C(=O)-NR6-, wherein R6 is selected from hydrogen, optionally substituted C1-12-alkyl, optionally substituted C1-12-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; and m is an integer of 0-12 and n is an integer of 0-12, wherein the sum m+n is 1-20; and R1 is selected from optionally substituted heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The compounds are usefuld for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT).
该申请公开了一种新型氰胍啶化合物,其化学式为(I),其中A从-C(=O)-,-S(=O)2-,-C(=S)-和-P(=O)(R5)-中选择,其中R5选择自C1-6-烷基,C1-6-烷氧基和羟基;B从单键,-O-,-NR6-和-C(=O)-NR6-中选择,其中R6选择自氢,可选择地取代的C1-12-烷基,可选择地取代的C1-12-烯基,可选择地取代的芳基,可选择地取代的杂环烷基和可选择地取代的杂环芳基;m为0-12的整数,n为0-12的整数,其中m+n之和为1-20;R1选择自可选择地取代的杂环芳基;以及其药学上可接受的盐和前药。这些化合物可用作治疗由烟酰胺磷酸核糖转移酶(NAMPRT)水平升高引起的疾病或病况的药物。